Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Исследование HYVET – важнейшее клиническое исследование 2008 г. в рейтинге Общества клинических исследований и Американской ассоциации сердца. 4 мая 2009 г. Атланта, Джорджия (США) - Журнал Системные Гипертензии №2 (2009)
Исследование HYVET – важнейшее клиническое исследование 2008 г. в рейтинге Общества клинических исследований и Американской ассоциации сердца. 4 мая 2009 г. Атланта, Джорджия (США)
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Ключевые слова: артериальная гипертония у пожилых, индапамид, периндоприл
________________________________________________
Полный текст
Список литературы
1. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
2. United Nations. World population ageing 1950–2050. IV. Demographic profile of the older population. Available from http://www.un.org/esa/population/publications/worldageing19502050/pdf/90chapteriv.pdf.
3. Leonetti G, Emeriau J-P, Knauf H et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005; 21: 37–46.
4. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 2008; 7: 683–9.
5. American Heart Association. News release. Top research advances include studies that influence medical care, apply science to «real world» communities. January 21, 2009. Available from http://americanheart.mediaroom.com/index.php?s=43&item=648.
6. Medscape Cardiology. This Year's Awards for the Most Important Trials Go to... HYVET and ACCOMPLISH. March 2, 2009. Available from http://cme.medscape.com/viewarticle/588818.
7. Faculty of 1000 Medicine. All time Top 10 by F1000 factor. All of Medicine. March 30, 2009. Available from http://www.f1000medicine.com/top10/ classics/.
8. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drugs Safety 2001; 24: 1155–65.
2. United Nations. World population ageing 1950–2050. IV. Demographic profile of the older population. Available from http://www.un.org/esa/population/publications/worldageing19502050/pdf/90chapteriv.pdf.
3. Leonetti G, Emeriau J-P, Knauf H et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005; 21: 37–46.
4. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 2008; 7: 683–9.
5. American Heart Association. News release. Top research advances include studies that influence medical care, apply science to «real world» communities. January 21, 2009. Available from http://americanheart.mediaroom.com/index.php?s=43&item=648.
6. Medscape Cardiology. This Year's Awards for the Most Important Trials Go to... HYVET and ACCOMPLISH. March 2, 2009. Available from http://cme.medscape.com/viewarticle/588818.
7. Faculty of 1000 Medicine. All time Top 10 by F1000 factor. All of Medicine. March 30, 2009. Available from http://www.f1000medicine.com/top10/ classics/.
8. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drugs Safety 2001; 24: 1155–65.
2. United Nations. World population ageing 1950–2050. IV. Demographic profile of the older population. Available from http://www.un.org/esa/population/publications/worldageing19502050/pdf/90chapteriv.pdf.
3. Leonetti G, Emeriau J-P, Knauf H et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005; 21: 37–46.
4. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 2008; 7: 683–9.
5. American Heart Association. News release. Top research advances include studies that influence medical care, apply science to «real world» communities. January 21, 2009. Available from http://americanheart.mediaroom.com/index.php?s=43&item=648.
6. Medscape Cardiology. This Year's Awards for the Most Important Trials Go to... HYVET and ACCOMPLISH. March 2, 2009. Available from http://cme.medscape.com/viewarticle/588818.
7. Faculty of 1000 Medicine. All time Top 10 by F1000 factor. All of Medicine. March 30, 2009. Available from http://www.f1000medicine.com/top10/ classics/.
8. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drugs Safety 2001; 24: 1155–65.
________________________________________________
2. United Nations. World population ageing 1950–2050. IV. Demographic profile of the older population. Available from http://www.un.org/esa/population/publications/worldageing19502050/pdf/90chapteriv.pdf.
3. Leonetti G, Emeriau J-P, Knauf H et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005; 21: 37–46.
4. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 2008; 7: 683–9.
5. American Heart Association. News release. Top research advances include studies that influence medical care, apply science to «real world» communities. January 21, 2009. Available from http://americanheart.mediaroom.com/index.php?s=43&item=648.
6. Medscape Cardiology. This Year's Awards for the Most Important Trials Go to... HYVET and ACCOMPLISH. March 2, 2009. Available from http://cme.medscape.com/viewarticle/588818.
7. Faculty of 1000 Medicine. All time Top 10 by F1000 factor. All of Medicine. March 30, 2009. Available from http://www.f1000medicine.com/top10/ classics/.
8. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drugs Safety 2001; 24: 1155–65.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.